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Background: Protein kinase C (PKC) regulates a variety of neural functions, including neurotransmitter release.
Although various PKC isoforms can be expressed at the synaptic sites and specific cell distribution may contribute
to their functional diversity, little is known about the isoform-specific functions of PKCs in neuromuscular synapse.
The present study is designed to examine the location of the novel isoform nPKCε at the neuromuscular junction
(NMJ), their synaptic activity-related expression changes, its regulation by muscle contraction, and their possible
involvement in acetylcholine release.
Results: We use immunohistochemistry and confocal microscopy to demonstrate that the novel isoform nPKCε is
exclusively located in the motor nerve terminals of the adult rat NMJ. We also report that electrical stimulation of
synaptic inputs to the skeletal muscle significantly increased the amount of nPKCε isoform as well as its phosphorylated
form in the synaptic membrane, and muscle contraction is necessary for these nPKCε expression changes. The results
also demonstrate that synaptic activity-induced muscle contraction promotes changes in presynaptic nPKCε through
the brain-derived neurotrophic factor (BDNF)-mediated tyrosine kinase receptor B (TrkB) signaling. Moreover, nPKCε
activity results in phosphorylation of the substrate MARCKS involved in actin cytoskeleton remodeling and related with
neurotransmission. Finally, blocking nPKCε with a nPKCε-specific translocation inhibitor peptide (εV1-2) strongly reduces
phorbol ester-induced ACh release potentiation, which further indicates that nPKCε is involved in neurotransmission.
Conclusions: Together, these results provide a mechanistic insight into how synaptic activity-induced muscle
contraction could regulate the presynaptic action of the nPKCε isoform and suggest that muscle contraction is an
important regulatory step in TrkB signaling at the NMJ.
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Figure 1 nPKCε and pnPKCε are expressed in adult and newborn
skeletal muscle. (A) Western blot analysis of nPKCε and pnPKCε
immunoreactivity in synaptic membrane in adult. (B) Western blot
analysis of the novel PKC isoform ε was carried out to determine its
presence in newborn (P6) and adult skeletal diaphragm muscle.
Samples were also immunoblotted with an anti-phospho-PKCε
antibody to identify specific phosphorylation of PKCε in resting
conditions. The predicted molecular weight of the isoform is indicated.
In all the experiments, we used actin as a loading control. The amount
of protein loaded in each lane was 15 μg.
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Protein kinase C (PKC) comprises a family of serine-
threonine protein kinases highly distributed in neural
and neuromuscular tissues and involved in neurotrans-
mitter release [1-5]. PKC isoforms, referred to as con-
ventional, novel and atypical types, are activated by
phosphatidylserine, diacylglycerol and/or Ca2+. Different
isoforms exhibit distinct tissue distributions and differ-
ent colocalizations of an activated PKC isoform with its
endogenous protein substrates contributes to the func-
tional diversity of the PKC isoforms [6,7]. Intracellular
PKC-binding proteins known as RACKs (receptors for
activated C-kinase) are essential to achieve the cellular
specific patterns of distribution of an individual activated
PKC isoform and therefore the functions of the PKC iso-
forms [8,9]. Therefore, the mechanisms that activate and
compartmentalize PKC isoforms must be identified if the
physiological functions of PKC are to be better understood.
Protein kinase C epsilon (nPKCε), a novel PKC iso-
form, is involved in the regulation of diverse cellular
functions. It is highly expressed in the brain and several
neural functions of nPKCε, including neurotransmitter
release, have been identified [10]. It has been shown by
Western blot analysis that nPKCε is also present in the
skeletal muscle [11,12]. However, to date, no reports
have been published on the localization and function of
the nPKCε at the paradigmatic neuromuscular junction
(NMJ). The present study is designed to examine the
distribution of nPKCε at the NMJ of the adult rat and to
know whether nPKCε level in synaptic membrane is
modulated by synaptic activity and muscle contraction.
Myristolyated alanine rich C kinase substrate (MARCKS),
a neuronal signal protein abundantly expressed in nerve
endings, is an actin cross-linking protein that is highly
phosphorylated on serine residues after PKC activation
[13-15]. In addition, nPKCε regulates large dense-core
vesicle release via phosphorylation of MARCKS [16].
MARCKS seems to be a key participant in actin cytoskel-
eton remodeling, which is the instrument to promote
transfer of synaptic vesicles to the plasma membrane, re-
lating thus MARCKS to neurotransmitter release [16-19].
Therefore, we studied if nPKCε activity results in phos-
phorylation of the substrate MARCKS at the NMJ. Finally,
we investigated the possible involvement of nPKCε in
ACh release.
We used immunohistochemistry and confocal micros-
copy to discriminate that nPKCε is exclusively located
in the nerve terminals at the NMJ. We also disrupted
the interaction between nPKCε and its specific RACK
(and therefore its activation) with an isozyme-selective-
translocation peptide inhibitor (εV1-2, [20]) in acute
biochemical and electrophysiological experiments that
also involved synaptic activity. We found that electrical
activity-induced muscle contraction promotes changesin presynaptic nPKCε level through TrkB activity and
that the nPKCε catalytic activity is related to the phos-
phorylation of MARCKS in an activity-dependent way.
The results also demonstrate that nPKCε is involved in
the PMA-induced ACh release mechanism at the NMJ.
Results
nPKCε and pnPKCε are expressed in adult and newborn
skeletal muscle
Western blot analysis using an antibody raised against
the novel PKC isoform ε was carried out to determine
the presence of the nPKCε isoform in young adult (P30-
P40) diaphragm skeletal muscle. We also immunoblotted
samples with an anti-phospho-PKCε antibody to identify
the specific phosphorylation of nPKCε that is a requisite
for PKC catalytic activity [21,22]. These experiments re-
vealed significant amounts of this isoform (Figure 1A).
The antibodies used only recognized the corresponding
protein, reacting with a band consistent with its predicted
molecular weight (manufacturer’s data sheets) (Figure 1A).
No nPKCε presence was observed in brain excised tissues
of KO mice in nPKCε, using this antibody [23]. Like other
PKC isoenzymes, nPKCε must be primed through phos-
phorylation to display full enzymatic activity and respond
to allosteric regulators.
We performed Western blot analysis and a quantita-
tive study (VersaDoc, Bio Rad, Hercules, CA) to analyze
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of the kinase isoform (and its phosphorylated form) in
both the newborn (P6) and the adult. The results show
that the expression of nPKCε isoform appears to be age-
dependent being nPKCε more abundant in the newborn
than in the adult (Figure 1B). Under resting conditions
(isolated muscle does not receive action potentials from
the motor neuron soma), we also found quite an abundant
level of phosphorylated nPKCε and also pnPKCε is more
abundant in the newborn than in the adult (Figure1B).
In conclusion, nPKCε is abundantly expressed and
phosphorylated in the skeletal muscle. Subsequently, im-
munohistochemical analyses were performed to identify
the cellular localization of the nPKCε isoform at the
adult neuromuscular junction components (ie. muscle
cells, Schwann cells or nerve terminals).
nPKCε isoform is located in the nerve terminal at the
neuromuscular junction
Immunofluorescence staining coupled with confocal mi-
croscopy analysis was performed to determine the pres-
ence and localization of this isoform at the adult NMJ.
Precise knowledge of the cellular localization of the
nPKCε in pre-, post- and/or perisynaptic elements is
crucial for elucidating the function/s of this protein. Im-
munofluorescence experiments were performed in the
diaphragm and LAL muscles and immunoreactivity for
nPKCε was identical in both muscles. All pictures in
Figure 2 show intense immunoreactivity for nPKCε in the
synaptic area identified with AChR labeling. Figure 2A
shows a NMJ with double labeling: AChRs in red and
nPKCε in green. Figure 2B shows a NMJ with triple label-
ing: AChRs in red, the Schwann cell in blue and nPKCε in
green. These figures show nPKCε-positive green immuno-
labeling concentrated at the presynaptic position over the
red postsynaptic gutters (asterisks). This can be seen both
in the semiconsecutive confocal sections (A2-4, B2-4) and
in the maximum projection (A1, B1) from the NMJs. The
glia and muscle cell do not seem to be labeled (Figure 2B).
In Figure 2A, it appears that pre-terminal axon is also
nPKCε-positive.
To improve the analysis of the cellular distribution of
the kinase at the NMJ we obtained semithin cross-
sections from whole-mount multiple-immunofluorescent
stained muscles [24]. We performed a triple staining in
which nPKCε isoform (in green in Figure 2C2) was colo-
calized with molecular markers of the three cellular ele-
ments in the NMJ: muscle cell (nAChR marked with
fluorescently labeled α-bungarotoxin, in red, Figure 2C3),
Schwann cell (S-100, in blue, Figure 2C4) and nerve ter-
minal (syntaxin and neurofilament, in blue, inset in C1)
(Figure 2C). When the nPKCε was co-stained with α-
BTX and S-100 (C1, colocalization picture), the nPKCε
immunofluorescence (in green) was shown as severalsmall granular areas located over the postsynaptic line of
the nAChRs (in red) and externally surrounded by the
Schwann cell (in blue). This label corresponds to the
axonal buttons of the nerve terminal because it is colo-
calized with the syntaxin/neurofilament stain (labeled in
blue in the inset in C1, Figure 2C) and also with syn-
taxin alone (not shown). Thus, the results indicate that
nPKCε has a unique location in the synapse: it is exclu-
sively expressed in the nerve terminals at the NMJ.
Denervation of the extensor digitorum longus muscle
(EDL) was performed to confirm that nPKCε is located
in the nerve. We denervated the muscle, waited 1–3
days, and studied the level of nPKCε by Western blots.
The results show that nPKCε protein almost completely
disappear after 1 day of denervation (ratio denervated/
control 0.11 ± 0.08, p < 0.05) indicating that the most
part of nPKCε is located in the nerve (Figure 2D). By
contrast, cPKCα, an isoform ubiquitously located [25],
slightly decreased (Figure 2D). Syntaxin has been used
as a control of denervation. The residual presence of
nPKCε may be related with blood vessels [11].
nPKCε expression is modulated by synaptic activity
Synaptic function of PKC family has been shown to be
regulated by activity [25], so we tested whether nPKCε
synaptic level is modulated by synaptic activity. There-
fore, we studied whether there was any change in the
amount of nPKCε and its phosphorylated form in the
synaptic membrane after electrical stimulation (with and
without muscle contraction). Electrical stimulation of
synaptic inputs to the diaphragm skeletal muscle (1 Hz
for 30 minutes) and the resulting muscle contraction
significantly increased the amount of nPKCε isoform
and its phosphorylated form in the synaptic membrane
(Figure 3A).
To separate the effect of the presynaptic stimulation
(and synaptic transmission) from the effect of the muscle
cell contraction, we performed experiments in which
contractions were inhibited. When the contraction was
inhibited by cutting the muscle fibers [26-28] or by using
μ-CgTx-GIIIB [28,29], the electrical stimulation signifi-
cantly decreased nPKCε and its phosphorylated form in
the synaptic membrane (Figure 3A). Thus, nerve stimu-
lation influences the kinase level in the synaptic mem-
brane and this suggest that, with stimulation, the kinase
could be detached from the membrane (and therefore
stop its catalytic function), or alternatively stimulation
entails some consumption of the enzyme. These results
clearly indicate that muscle contractions induce an im-
portant change that reverses the effect of nerve stimula-
tion by itself on nPKCε level in the synaptic membrane,
suggesting that muscle contraction is necessary for nPKCε
maintenance and its catalytic activity. Moreover, we per-
formed several Western blots of nPKCε and pnPKCε to
DFigure 2 nPKCε isoform is located in the nerve terminal at the adult neuromuscular junction. (A1) shows a reconstruction of a NMJ
stained for AChRs with fluorescent α-Bungarotoxin in red and immunolabeled with an antibody against nPKCε isoform in green. (A2-A4), several
semiconsecutive confocal optical sections from the same NMJ shown in A1. The (*) indicates nPKCε-positive nerve terminal buttons accommodated in
the AChRs delimited synaptic gutters. (B1) shows a reconstruction of a NMJ triple labeled for AChRs (fluorescent α-BTX in red), the Schwann cell
(immunolabeled with an anti S-100 antibody in blue) and nPKCε isoform in green. (B2-B4), several confocal sections from the same NMJ shown in B1.
The (*) also indicates nPKCε-positive granular immunolabeling concentrated on the nerve endings position over the synaptic gutters. The glia and
muscle cell are not labeled. (C), Immunohistochemistry in semithin sections from a whole-mount multiple-immunofluorescent stained muscle. In the
colocalization picture (C1), the triple staining that labeled nPKCε in green (C2), AChRs in red (C3) and Schwann cells in blue, (C4) shows the nPKCε
immunolabel only in the middle of the sandwich formed by glia and muscle cell. In the inset (C1), the control triple staining that labeled PKCε (in
green), AChRs (in red) and the nerve terminal (NT, in blue, neurofilament-200/syntaxin) shows that the nPKCε and nerve terminal markers are well
colocalized. The bars in (A), (B) and (C) indicate 10 μm. The bar in the inset indicates 2.5 μm. The NMJ are from LAL muscles. (D) Western blot analysis
of nPKCε, pnPKCε, cPKCα and syntaxin in denervated EDL muscle.
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traction (cut and μ-CgTx GIIIB (μCTX)). Quantitative
data show that (Figure 3B): (1) levels of nPKCε and
pnPKCε are not significantly different in cut muscles and
in muscles where muscle contraction was abolished by
μ-CgTx GIIIB (μCTX); (2) nPKCε and pnPKCε signifi-
cantly decreases in electrically stimulated intact muscles
where muscle contraction was abolished by μCgTx
GIIIB (ES/μCTX) in a similar way as occurs in electric-
ally stimulated muscles where muscle contraction was
abolished by cut (ES/Cut); (3) There are no significantdifferences between ratios μCTX vs Cut. These results
eliminate any possible artifact due to the method used
to abolish muscle contraction.
Electrical activity-induced muscle contraction promotes
changes in nPKCε through TrkB activity
The results set out above (Figure 3A) show that, in con-
tracting muscles, the level of nPKCε are highly increased
relative to the stimulated and non-contracting muscles,
but also relative to the non-stimulated muscles. The


















































Figure 3 nPKCε expression is modulated by synaptic activity. (A) Western blot analysis of nPKCε and pnPKCε immunoreactivity levels in
synaptic membrane in adult stimulated muscles with (ES + C) and without (ES) muscle contraction. (B) shows Western blots of nPKCε to compare
the effect of the method to abolish muscle contraction (cut and μ-CgTx GIIIB (μCTX)). Quantitative data eliminate any possible artifact due to the
method used to abolish muscle contraction. There are no significant differences between ratios μCTX vs Cut. The Western blot shows: (1) levels
of nPKCε in non-stimulated muscles where no method was performed to abolish muscle contraction (Ctr), in cut muscles (Cut) and in muscles
where muscle contraction was abolished by μ-CgTx GIIIB (μCTX); (2) nPKCε in electrically stimulated intact muscles where muscle contraction was
abolished by μCgTx GIIIB (ES,μCTX); and (3) nPKCε in stimulated muscles resulting in contraction (ES + C). Experiments were performed using
diaphragm muscle.
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nPKCε is decreased. Thus, we hypothesize that muscle
contraction induces a change that can reverse the effect
of nerve stimulation itself and a contraction-dependent
neurotrophic support from postsynaptic site may make a
contribution to this through the tyrosine kinase receptor
B (TrkB). To demonstrate whether the activation of
TrkB, as a result of muscle contraction, is critical to
affect nPKCε’s level, we selectively suppressed TrkB ac-
tivity in contracting diaphragm muscles using selective
TrkB inhibitors. We used ANA-12 which showed direct
and selective binding to TrkB and inhibits processes
downstream of TrkB without altering TrkA and TrkC
functions [30]. ANA-12 fully inhibits BDNF-induced
TrkB phosphorylation and therefore prevents receptor
activation. We also used an anti-TrkB antibody (47/TrkB)
which effectively inhibits BDNF binding to TrkB recep-
tors [31]. We measured resultant nPKCε and pnPKCε
levels and found that TrkB blockade resulted in a signifi-
cant decrease in the isoform (Figure 4). We obtained the
same result with the two blockade methods. These re-
sults demonstrate that electrical activity-induced muscle
contraction promotes increase in nPKCε and pnPKCεthrough TrkB activity suggesting that muscle contraction
induce an increase of the interaction of a TrkB-specific
neurothrophic factor with TrkB that enhance the intra-
cellular signaling to increase the isoform levels in the
synaptic membrane. Accordingly, exogenously added
BDNF (10 nM, 30 minutes) in stimulated muscles with-
out contraction significantly increased the amount of
pnPKCε (58.78% ± 2.1% of change, p < 0.05). This result
indicates that exogenous BDNF mimics muscle contrac-
tion effect on nPKCε levels. We choose the BDNF dose
based in a previous dose–response and time-course
study in the same muscle to determine their effect on
the size of the evoked EPP [32].
nPKCε regulates phosphorylation of MARCKS in skeletal
muscle, in an activity-dependent way
To gain insight into the role of nPKCε we analyzed pos-
sible substrate phosphorylation. Although the transloca-
tion and phosphorylation of PKC is indicative of PKC
activation [33], a more direct measure of the PKC activ-
ity is to detect PKC substrate phosphorylation in cells.
Therefore, we wanted to know whether MARCKS phos-
















































Figure 4 Electrical activity-induced muscle contraction
promotes changes in nPKCε isoform through trkB activity.
Western blot analysis of nPKCε and pnPKCε immunoreactivity levels
in adult contracting muscles (ES + C) in the presence or not of the
TrkB inhibitor Ana12 (A) or anti-TrkB antibody (47/TrkB) (B). In all the
muscles, the phrenic nerve was stimulated at 1 Hz for a 30-minute
period and muscle contraction was not prevented. The quantitative
histograms show the changes in (ES + C) with TrkB inhibitor with
respect to (ES + C) and normalized with actin. The data are mean ±
SD values from at least 5 independent experiments. *p < 0.05.
Experiments were performed using diaphragm muscle.
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tivity (with and without muscle contraction).
We used the nPKCε-specific translocation inhibitor
peptide, epsilonV1-2 (εV1-2; [20]), to block the isoform
activity. We first wanted to show that the peptide εV1-2
inhibits the presence of nPKCε and pnPKCε in the syn-
aptic membrane of the diaphragm muscle. Figure 5A
shows that incubation with the peptide εV1-2 (100 μM)
produces a rapid (10 min) and significant decrease in
nPKCε and pnPKCε that is maintained after 60 minutes
of incubation with the peptide (not shown). This de-
crease in the level of the nPKCε and pnPKCε induced by
incubation with εV1-2 suggests that the nPKCε isoform
may be tonically involved in some nerve terminal mech-
anism. No change in the level of the nPKCε and pnPKCε
was observed in the presence of 100 μM of the scram-
bled peptide (not shown). Furthermore, the inhibition of
nPKCε by the peptide has a different effect on nPKCε
and pnPKCε (nPKCε decreases a 70% while pnPKCε a
40%). In this context, Figure 5A also shows that Hsp70
(heat shock protein 70), which has a role in prolonging
the lifetime of activated PKC, significantly increases in
the presence of the inhibitor peptide of nPKCε. This
suggests a major interaction of Hsp70 with pnPKCε, whichcould prolong the lifetime of active nPKCε (pnPKCε) and
sustain its function.
Next, we looked for pMARCKS expression in the skel-
etal muscle and in denervated muscle. Figure 5B shows
the time course of the level of pMARCKS in diaphragm
muscle in resting conditions indicating that skeletal
muscle expresses pMARCKS and that pMARCKS is
quite stable after muscle dissection. Denervation of EDL
muscle totally removes pMARCKS (Figure 5C) indicat-
ing its presynaptic location. Note that syntaxin, a mol-
ecule exclusively located in the presynaptic component
at the NMJ that has been used as a control, also disap-
pears after denervation.
We next studied whether MARCKS phosphorylation is
dependent on nPKCε in the skeletal muscle. Figure 5A
shows that incubation for 10 minutes of the muscles
with the peptide εV1-2 produces a significant decrease
in pMARCKS indicating that nPKCε is related to the
phosphorylation of MARCKS in the skeletal muscle.
To determine whether stimulation (synaptic activity by
itself, without muscle contraction) induces nPKCε phos-
phorylating activity on MARCKS in skeletal muscle, we
subjected the protein extracts of stimulated muscles to
phospho-MARCKS immunoblotting. WB analysis shows
a significant increase in pMARCKS at 10 minutes indi-
cating that phosphorylation of MARCKS depends on
synaptic activity by itself (Figure 6A). In this condition,
Hsp70 is also increased suggesting that pnPKCε could be
stabilized by Hsp70 and therefore the kinase placed in the
membrane could continue regulating the phosphorylation
of MARCKS and increasing its amount. To further relate
the effects of electrical activity and nPKCε activity we
stimulated muscles previously incubated (100 μM, 30 mi-
nutes) with the blocking peptide (Figure 6B). We
found a significant decrease in pMARCKS level,
which emphasizes the role of nPKCε in MARCKS
phosphorylation depending on the presynaptic activity.
According, nPKCε and pnPKCε significantly decreased
in these same conditions (Figure 6C) indicating also a
possible additive effect and suggesting different levels
in the modulation of nPKCε expression. Incubation
with the inactive peptide (Vs) did not modify the level
of the isoform obtained with electrical stimulation
(Figure 6C).
To test whether muscle contraction has an additional
effect on MARCKS phosphorylation, we also analyzed
pMARCKS level in electrical stimulated contracting
muscles. Electrical stimulation accompanied by contrac-
tion (for 30 minutes) significantly increased the phos-
phorylation of MARCKS when compared with synaptic
activity by itself (ES) (Figure 7A), indicating that synaptic
activity with muscle contraction has a higher effect on
the MARCKS phosphorylation than presynaptic activity
by itself.
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Figure 5 nPKCε regulates phosphorylation of MARCKS in skeletal muscle. (A) shows the Western blotting analysis of nPKCε, pnPKCε,
pMARCKS and Hsp70 in control adult muscles (Ctr) and after incubation with peptide εV1-2 (10 min). (B) shows the time course of the level of
pMARCKS in adult diaphragm muscle in resting conditions after muscle dissection. (C) shows the Western blotting analysis of pMARCKS and syntaxin
in denervated EDL muscle. The quantitative histograms in A and C show the percentage of changes respect to the control and normalized with actin.
The data are mean ± SD values from at least 5 independent experiments. *p < 0.05. Experiments were performed using diaphragm muscle.
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promotes changes in nPKCε through TrkB activity, next,
we plan to know whether muscle contraction could affect
MARCKS phosphorylation through TrkB activity. Thus,
we analyzed the amount of pMARCKS in contracting
muscles in which has been selectively inhibited TrkB ac-
tivity using the anti-TrkB antibody (47/TrkB) or the fusion
protein trkB-Fc (to chelate endogenous BDNF/NT-4). We
found that TrkB blockade resulted in a significant de-
crease in pMARCKS (Figure 7B). We obtained the same
result with the two blockade methods. These results dem-
onstrate that electrical activity-induced muscle contraction
promotes changes in pMARCKS through TrkB activity.
In summary, the data in this section indicates that
nPKCε regulates phosphorylation of MARCKS in NMJ
nerve terminal and that presynaptic activity enhances
nPKCε-dependent MARCKS phosphorylation. Moreover,
the synaptic activity-induced muscle contraction further en-
hances MARCKS phosphorylation throughTrkB signaling.
PMA-induced PKC-coupling to ACh release potentiation
involves nPKCε
It is currently believed that PKCs can be strongly activated
by such phorbol esters as phorbol 12-myristate 13-acetate
(PMA), which potentiates ACh release. Therefore, al-
though it has been reported that PMA has targets other
than PKC for regulating neurotransmission [34,35], it should
be determined whether the nPKCε plays a role in PMA-
induced ACh release.The histogram in Figure 8A shows that evoked ACh
release can be strongly increased by incubation of the
diaphragm muscle with PMA (raw data in Figure 8B left;
see also [5,28,36]). Blocking the nPKCε isoform at low
concentrations of the peptide εV1-2 (1 and 10 μM) sig-
nificantly reduces the effect of PMA (~60%; raw data in
Figure 8B right) whereas at high concentrations of εV1-2
(100 μM) PMA no longer potentiates ACh release. Data
in Figure 8A are quantal content (the quantal content –
M- was estimated with the direct method by recording
mEPPs and EPPs simultaneously and then calculating
the ratio: M = Average Peak EPP/Average Peak mEPP)
and therefore reflects a presynaptic effect of εV1-2 on
PMA-induced ACh release potentiation. To further dis-
card any postsynaptic contribution we measured the
average amplitude of the mEPPs after incubation with
εV1-2 (1–100 μM) and PMA together or separately and
found no difference above a non-significant 9% (P > 0.05)
as compared with the non-incubated control. We con-
clude that nPKCε was activated by PMA and then coupled
to potentiate release. Inhibition with the peptide εV1-2
eliminates the contribution of the epsilon isoform and,
therefore, the PMA-induced PKC-coupling to ACh release
potentiation significantly involves nPKCε activation.
These results suggest that nPKCε is involved in control-
ling transmitter release at the NMJ. It remains to further
determine the specific mechanism of its contribution.
However, bearing in mind all the results, we conclude that





































































Figure 6 nPKCε regulates phosphorylation of MARCKS in adult skeletal muscle, in an activity-dependent way. (A) shows the Western
blotting analysis of pMARCKS and Hsp70 in control (Ctr) and in stimulated muscles (ES). (B) shows the effects of εV1-2 incubation and electrical
activity (V + ES) on the amount of pMARCKS. (C) shows the Western blotting analysis of nPKCε and pnPKCε in several conditions of stimulation: in
control (Ctr), in stimulated muscles (ES), in stimulated muscles previously incubated with the blocking peptide (V + ES), in stimulated muscles
previously incubated with the inactive peptide (Vs + ES). In all these experiments, the phrenic nerve was stimulated at 1 Hz for a 30-minute period
and muscle contraction was prevented. The data are means ± SD values from at least 5 independent experiments and are normalized with actin.
*p < 0.05. Experiments were performed using diaphragm muscle.
Obis et al. Molecular Brain  (2015) 8:8 Page 8 of 16presynaptic component of the NMJs and it is involved in
the PMA-induced transmitter release mechanism at the
NMJ. Moreover, synaptic activity-induced muscle contrac-
tion enhances nPKCε, and its catalytic function to increase
phosphorylation of MARCKS, through TrkB activity.
Discussion
Recent studies provide evidence that nPKCε could regu-
late distinct aspects of neural functions, including neuro-
transmitter release and signal transduction [10,37]. Here,we have examined the presence of the nPKCε in the adult
NMJ, its synaptic activity-related expression, its regulation
by muscle contraction and its involvement in ACh release.
nPKCε expression and localization at the NMJ
It has been shown by Western blot analysis that nPKCε
is widely distributed in the central nervous system [10]
and skeletal muscle [11,12]. There is also a predominant
presence of nPKCε mRNA in the brain [38,39]. Substan-



















































Figure 7 Muscle contraction enhances phosphorylation of MARCKS through TrkB. (A) shows the Western blotting analysis of pMARCKS in
synaptic membrane in adult stimulated muscles with (ES + C) and without (ES) muscle contraction. (B) shows the Western blot analysis of
pMARCKS immunoreactivity levels in adult contracting muscles (ES + C) in which has been selectively inhibited TrkB activity using the anti-TrkB
antibody (47/TrkB) or the fusion protein trkB-Fc (to chelate endogenous BDNF/NT-4). In all these experiments, the phrenic nerve was stimulated
at 1 Hz for a 30-minute period and muscle contraction was prevented (ES) or not (ES + C). The data are means ± SD values from at least 5 independent
experiments and are normalized with actin. *p < 0.05. Experiments were performed using diaphragm muscle.
Obis et al. Molecular Brain  (2015) 8:8 Page 9 of 16in the rat brain, even at birth but a considerable increase
was observed 1–2 weeks postnatal, which suggests that
nPKCε is involved in constructing neural networks be-
cause it coincides with synapse formation [10]. Likewise,
we found that substantial amounts of nPKCε were
expressed in the rodent skeletal muscle being more abun-
dant during the development than in the adult (roughly
twice).
nPKCε and its phosphorylated form are located in the
membrane fraction of the synapse-containing zone of
the adult skeletal muscle. Furthermore (in correspond-
ence with the denervation experiments), we localized
nPKCε in the motor nerve terminals at the adult NMJ
but not in the Schwann and postsynaptic muscle cells.
Immunohistochemistry performed in the central nervous
system reveals that the enzyme is most abundantly
expressed in the hippocampus [10,40]. Interestingly, the
immunoreactivity of the protein is evident in the nerve
fibers and precise observation using electron microscopy
reveals its presynaptic localization [6,40] as we found in
the NMJ. These findings strongly indicate that nPKCε
may be involved in presynaptic functions such as neuro-
transmitter release in mature synapses.
Synaptic activity, nPKCε and pMARCKS
Because the synaptic function of PKC family is regulated
by activity [25], we investigated whether synaptic activity
regulates the translocation to the synaptic membrane of
nPKCε and its phosphorylated form (which is an indica-
tion of its activation). Furthermore, because it has been
reported that electrical stimulation-induced contractionincreases the translocation of PKC to the membrane
[25,41-43], we also wanted to study separately the effect
on nPKCε of the presynaptic stimulation and synaptic
transmission from the possible effect of the muscle cell
contraction. Our results suggest that nPKCε has a role
in some activity-related mechanism at the NMJ, and that
muscle activity has an important impact on it. We found
that electrical stimulation of synaptic inputs to the skeletal
muscle and the resulting muscle contraction significantly
increased the amount of nPKCε and its phosphorylated
form in the synaptic membrane (Figure 3A). When the
contraction was inhibited by cutting the muscle fibers
[26-28] or by using μ-CgTx-GIIIB [28,29], electrical stimu-
lation resulted in a significant decrease of nPKCε in the
membrane (Figure 3). These results clearly indicate that
muscle contraction induces an important signaling that
reverses the effect of nerve stimulation by itself on nPKCε
level in the synaptic membrane, suggesting that contrac-
tion is a necessary condition for the nPKCε catalytic func-
tion. A similar action of the muscle contraction related to
cPKC isoforms has been previously described [25].
What could be the physiological significance of nPKCε
levels being downregulated functionally by ES and, at
the same time, being up-regulated by muscle contrac-
tion? The analysis of the substrate phosphorylation by
nPKCε could help. Because there are no known nPKCε-
specific substrates, we used MARCKS for several reasons.
MARCKS is a widely distributed actin cross-linking pro-
tein that is highly phosphorylated on serine residues after
PKC activation [13-15]. The phosphorylation of MARCKS
has been used to assess both the activation and inhibition
PMA V1-2 (1µM) PMA
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Figure 8 PMA-induced PKC-coupling to ACh release potentiation
involves nPKCε. The histogram in (A) indicates that ACh release is
increased by incubation with PMA. The dose-dependence analysis of
the effect of the εV1-2 shows that the previous block of the nPKCε
reduces (1 and 10 μM) and even abolishes (100 μM) the PMA potentiation
of ACh release. For each kind of experiment: n = 5 adult muscles and a
minimum of 15 fibers per muscle. *means p < 0.05. (B) shows the raw
data of superimposed EPPs in the conditions described. Thus, the
integrity of nPKCε seems a necessary condition if the PMA-induced
transmitter release potentiation is to be fully expressed. Vertical bars:
left, 10 mV; right, 5 mV. Horizontal bars: 4 ms. Experiments were
performed using diaphragm muscle.
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pant in actin cytoskeleton remodeling, which is the instru-
ment to promote transfer of synaptic vesicles to the
plasma membrane, relating thus MARCKS to neurotrans-
mitter release [17]. In addition, nPKCε regulates large
dense-core vesicle release via phosphorylation of MARCKS
[16]. Our results show that MARCKS phosphorylation is
dependent on nPKCε at the NMJ and its phosphorylation
depends on the synaptic activity (with and without muscle
contraction). Thus, the increase in the amount of the
nPKCε and pnPKCε in the synaptic membrane after
muscle contraction is in concordance with the increased
phosphorylation of the PKC substrate MARCKS (Figure 7A).
However, the results also show that nPKCε dependent-
phosphorylation of MARCKS occurs when there is not
muscle contraction (Figure 6A-B), indicating that pre-
synaptic activity by itself is enough to induce some in-
crease in pMARCKS. Nevertheless, pMARCKS is muchhigher in contracting muscles than in stimulated muscles
without contraction (Figure 7A). Thus, it seems that the
amount of pMARCKS depends on the amount of nPKCε
active (which is higher when muscle contraction occurs)
and, therefore, muscle contraction is necessary as a
mechanism to increase the nPKCε level in the synaptic
membrane. Interestingly, when nPKCε translocation is
inhibited by εV1-2 in nerve-stimulated muscles, both
nPKCε (Figure 6C) and pMARCKS (Figure 6B) sig-
nificantly decrease indicating not only, as indicated
above, that synaptic activity-induced phosphorylation
of MARCKS depends on catalytic function of nPKCε,
but also that activity-dependent nPKCε activation could
results in its sustained work (may be to regulate phosphor-
ylation of MARCKS) and subsequently in its detachment
from the membrane that eventually could result in deg-
radation or downregulation of the enzyme. In these condi-
tions, Hsp70 (a heat shock protein which has a role in
prolonging the lifetime of activated PKC) significantly in-
creases (Figure 6A) suggesting a major interaction of
Hsp70 with pnPKCε, which could prolong the lifetime of
active nPKCε (pnPKCε) and sustain its function to pro-
mote phosphorylation of MARCKS. Together, these re-
sults indicated that synaptic activity by itself could activate
nPKCε to enhance MARCKS phosphorylation at the NMJ
and that muscle contraction could be necessary as a
mechanism to increase the pnPKCε and pMARCKS levels.
It has been described in other synapses and systems a
link between phosphorylation of MARCKS and nPKCε
[16,45,46]. However, because MARCKS can be phosphor-
ylated by other PKCs we cannot fully discount that
isoforms other than nPKCε phosphorylate this PKC-
substrate in response to the increased activity, and re-
lated to the nPKCε activity, or even that other kinases are
involved [47,48].
On the other hand, the blockade, in not stimulated
muscles, of the translocation of nPKCε (and therefore its
phosphorylating activity) with the εV1-2 peptide, de-
creased the level of nPKCε and pnPKCε (see Figure 5A).
We interpret this result as the nPKCε activity inhibition
as a result of the incubation with the specific transloca-
tion inhibitor peptide. This can be confirmed because
the decrease in nPKCε is accompanied by a parallel de-
crease in pMARCKS (Figure 5A), which indicates not
only that this isoform plays a role in phosphorylating
MARCKS but also that the inhibitor peptide acts on the
epsilon isoform.
Effect of synaptic activity-induced contraction on nPKCε
through TrkB activity
How is nPKCε level increased when muscle contraction
is not prevented? Recently, several evidence support
muscle activity-dependent BDNF and TrkB signaling as
a key regulator of neuromuscular function. First, BDNF
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human skeletal muscle [49]. Secondly, basal levels of
neuromuscular activity are required to maintain normal
levels of BDNF in the neuromuscular system [50]. Fi-
nally, BDNF and TrkB contribute to the neuromuscular
junction transmission [32,51]. Accordingly, we aimed to
investigate whether nerve induced-muscle activity would
produce a neurotrophin inducing a signaling pathway
through TrkB to affect presynaptic nPKCε and its cata-
lytic activity. Our results show that blockade of TrkB
prevents muscle contraction-induced nPKCε increase
(Figure 4A-B) and phosphorylation of MARCKS (Figure 7B)
indicating that a neurotrophin acts through TrkB to in-
crease nPKCε and pMARCKS on the nerve terminal.
Moreover, we found that phosphorylation of nPKCε in-
creases significantly when stimulated muscles were incu-
bated with BDNF exogenous, indicating that BDNF could
be the neurothrophin that activates TrkB to enhance
nPKCε action and pMARCKS on the nerve terminal. It
could be speculated that TrkB works to regulate nPKCε
(and pnPKCε) by phosphorylating PLCγ (phosphoinosi-
tide-specific phospholipase C γ). Phosphorylation of TrkB
on Tyr785 recruits PLCγ to the receptors, and the enzyme
becomes activated upon tyrosine phosphorylation [52,53].
Activated PLCγ hydrolyses PI(4,5)P2 (phosphatidylinositol
4,5-biphosphate) to generate inositol tris-phosphate (IP3)
and DAG, which activates nPKCε (once the isoform has
been previously phosphorylated by PDK (3-phosphoinosi-
tide dependent protein kinase) and autophosphorylated
[54-56]. These findings provide mechanistic insight into
how synaptic activity induced-muscle contraction could
regulate the presynaptic action of the nPKCε and suggest
that muscle contraction is an important regulatory step in
TrkB signaling at the NMJ.
Effect of nPKCε on PMA-induced PKC-coupling to ACh
release potentiation
One aim of the present study is to determine whether
nPKCε is involved in the neurotransmission mechanism.
Although it has been reported that PMA has targets other
than PKC for affecting neurotransmission (Munc13)
[34,35], PMA strongly activates PKC family to enhance
neurotransmission [5,36,57-60]. Here, we show that block-
ing the nPKCε with εV1-2 fully inhibited (Figure 8) the
PMA-induced pharmacologic potentiation of ACh release
in a concentration-dependent way indicating that nPKCε
plays a role in neurotransmission at the NMJ. Therefore,
nPKCε has a key role regulating the ACh release by itself
or by modulating the action of other PKCs isoforms. It
has been demonstrated that PKC family is involved in the
modulation of ACh release at the NMJ [60]. Moreover, ex-
ogenously added BDNF potentiates evoked ACh release in
a TrkB receptor dependent manner [32]. Furthermore, the
TrkB signaling needs an operative PKC pathway to coupleto the release mechanism and potentiate it [61]. nPKCε
could be related with this PKC-TrkB mechanism that
modulates ACh release at the NMJ. Future experiments
will be necessary to determine how nPKCε is critical to
the maintenance of transmitter release and to better
understand how muscle contraction-induced phosphoryl-
ation of MARCKS, regulated by nPKCε, is involved in
neuromuscular transmission. Furthermore, nPKCε may
work in parallel with the active zone positioning and prim-
ing protein Munc13 to enhance neurotransmission be-
cause recent studies proposed two probably converging
pathways stimulated by phorbol esters (and DAG) to in-
duce potentiation (PKC- and Munc13-dependent) [62,63].
It has been proposed that a PKC/Munc18-1 dependent-
redistribution of synaptic vesicles after phorbol ester
stimulation (via PKC phosphorylation of the SNARE/SM
fusion protein Munc18-1), may be the morphological
correlate of the increased release efficiency during potenti-
ation [62]. In this redistribution, MARCKS may be in-
volved because their role in actin cytoskeleton remodeling,
which is the instrument to promote transfer of synaptic
vesicles to the plasma membrane.
In physiological conditions, nerve action is linked to
muscle contractions, therefore it is important to provide
a mechanism linking muscle contraction to nerve func-
tion. Figure 9 shows a diagram illustrating how synaptic
activity-induced muscle contraction could regulate the
presynaptic action of the nPKCε through TrkB signaling
to enhance phosphorylation of MARCKS that could be
related to the neurotransmitter release.
Conclusion
In summary, our results indicate that nPKCε is exclusively
located in the presynaptic component of the NMJs, is reg-
ulated by synaptic activity involving muscle contraction
through TrkB function to enhance phosphorylation of
MARCKS and finally, nPKCε is involved in ACh release.
Material and methods
Animals
Diaphragm and levator auris longus (LAL) muscles of
young adult and postnatal male Sprague–Dawley rats (30–
40 and 6 days; Criffa, Barcelona, Spain) were used to
perform stimulation experiments, immunohistochemistry
and electrophysiological experiments. Denervation experi-
ments were performed in the extensor digitorum longus
muscle (EDL). The animals were cared for in accordance
with the guidelines of the European Community Council
Directive for the humane treatment of laboratory animals.
Materials
Antibodies
Primary antibodies used for Western blot and immuno-
histochemistry analysis were obtained from different
Figure 9 Diagram of proposed mechanism mediating activity-
dependent regulatory function of nPKCε on ACh release linked
to muscle contraction. The diagram illustrates how synaptic activity
induced-muscle contraction could regulate the presynaptic action of
the nPKCε through TrkB signalling in the neurotransmission release.
The activity of the nPKCε isoform requires muscle cells to contract if
the presynaptic membrane level of nPKCε is to be maintained or
increased (probably with the involvement of the stabilizing action of
HSP70). Finally, we hypothesize that nPKCε is functionally related in
the neurotransmission mechanism on the NMJs.
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PKCε (Ser729) and rabbit anti-PKCα polyclonal anti-
bodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA); rabbit anti-PKCε and rabbit anti-
phospho-PKCε (Ser729) polyclonal antibodies were ob-
tained from Upstate Biotechnology (Millipore, Lake Place
NY); mouse anti-PKCα monoclonal antibody was pur-
chased from BD Transduction Laboratories (Lexington,
KY); rabbit anti-phospho-MARCKS (myristoylated alanine-
rich C kinase substrate) (S152/S156) polyclonal antibody
from R&D systems (Biotecnology, Minneapolis); rabbit
anti-HSP70/HSP72 polyclonal antibody from Enzo (Life
Sciences, Inc.); goat anti-GAPDH from Imgenex (San
Diego, CA) and rabbit anti-pan-actin polyclonal antibody
from Cell Signaling Technology, Inc (Beverly, MA). The
secondary antibodies used in the Western blot were goat
anti-mouse and donkey anti-rabbit conjugated to HRP
(Horseradish Peroxidase) from Jackson Immunoresearch
and rabbit anti-goat HRP from Molecular Probes (Eugene,
OR). For the immunohistochemistry we also used anti-
bodies that are commonly used as markers to differentially
detect the parts of the NMJ (syntaxin, neurofilament-200
and S100): the mouse monoclonal antibody and the rabbit
polyclonal anti-syntaxin antibody (Sigma, St Louis, MO);
the monoclonal and polyclonal anti-neurofilament-200
antibodies (Sigma, St Louis, MO); the rabbit anti-S100
antibody (Dako, Carpinteria, CA) and the mouse anti-S100
antibody (Acris, Germany). The secondary antibodies used
were donkey anti-rabbit or anti-mouse conjugated to
Alexa Fluor 488 and Alexa Fluor 647 from Molecular
Probes (Eugene, OR). Postsynaptic acetylcholine receptors
(AChRs) were detected with α-bungarotoxin (α-BTX) con-
jugated to tetramethyl rhodamine iso-thiocyanate (TRITC)
from Molecular Probes (Eugene, OR).
As a control, the primary antibodies were omitted from
some muscles during the immunohistochemical and
Western blot procedures. These control muscles never ex-
hibited positive staining or revealed bands of the appropri-
ate molecular weight with the respective procedures. In
double-staining protocols, omitting either one of the two
primary antibodies completely abolished the correspond-
ing staining and there was no cross-reaction with the other
primary antibody. Pretreatment of a primary antibody with
an excess of the appropriate blocking peptide (between
three- and eightfold by weight) in skeletal muscle tissue
prevented immunolabeling. All the primary antibodies
used detect a single band with the referenced molecular
weight on Western blot (manufacturer’s data sheets; see
also Figure 1 for nPKCε and pnPKCε skeletal muscle).
Reagents
For the different treatments we used substances that
modulate PKC activity: Phorbol 12-myristate 13-acetate
(PMA, Sigma) was made up as 10 mM stock solution indimethylsulfoxide (DMSO; Tocris, Ellisville, MO, USA).
The working solution was PMA 10 nM. εV1-2, nPKCε-
specific translocation inhibitor peptide (myristoylated
PKC-ε V1-2 peptide, EAVSLKPT) from Calbiochem
(Merk, Germany) was made up as 1 mM in distilled water
or normal Ringer solution. Working solutions were 1, 10
and 100 μM. As a negative control of the nPKCε-specific
translocation inhibitor peptide we used scrambled εV1-2
peptide (εV1-2-s, LSETKPAV), containing the same ami-
noacids as the inhibitor peptide but in a different se-
quence, from Calbiochem (Merk, Germany). Working
solutions were 1, 10 and 100 μM.
TrkB receptor-inhibitors
The TrkB ligand N2-(2-{[(2-oxoazepan-3-yl)amino]car-
bonyl}phenyl)benzo[b]thiophene-2-carboxamide (ANA-
12; cat. no. BTB06525; MW 407.5 g/mol) was purchased
from Maybridge (Cornwall, UK) and was made up as a
10 mM in DMSO. Anti-TrkB (clone 47/TrkB; cat. no.
610102; 250 μg/ml) was obtained from BD Transduction
Laboratories (Lexington, KY). Recombinant human trkB/
Fc Chimera (trkB-Fc; 688-TK from R&D Systems, Minne-
apolis), 100 μg/ml. Working solutions: ANA-12, 10 μM;
anti-TrkB, 10 μg/ml; trkB-Fc, 1–5 μg/ml.
Stimulation of the muscle and incubations with εV1–2
peptide and PMA
In all the experimental protocols, the diaphragm muscle
from young adult rats were excised together with the
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(see below) continuously bubbled with 95% O2/5% CO2
at room temperature. To stimulate the muscle, the
phrenic nerve was stimulated at 1 Hz for a 10- or 30-
minute period by an A-M Systems 2100 isolated pulse
generator (A-M System, Carlsborg, WA). To study sep-
arately the effect of the presynaptic stimulation (and
synaptic transmission) from the effect of the muscle cell
contraction, we performed experiments in which con-
tractions were prevented (ES) or not (ES + C). The
muscle was prevented from contracting by cutting on ei-
ther side of the main intramuscular nerve branch (see
below). We also performed experiments to discard any
possible artifact due to the muscle fiber cutting. Cut
muscles were compared with muscles where muscle
contraction was abolished by using μ-conotoxin GIIIB
(μ-CgTx-GIIIB, 3 μM −1.5 μM, from ICS, International
Clinical Service GmbH, München). The two methods
used to prevent muscle contraction did not show differ-
ences with regard to electrophysiological parameters of
the neurotransmission (see also later in Results).
We used a nonpharmacological tool to inhibit specific-
ally nPKCε isoform. We used the nPKCε-specific trans-
location inhibitor peptide, epsilonV1-2 (εV1-2; [20]), to
block the isoform activity so that we could analyze its
possible constitutive involvement in cell functions in the
resting and stimulated NMJs. This peptide interferes in
the nPKCε interaction with the anchoring protein
epsilon-RACK and, therefore, inhibits the anchoring of
nPKCε near its substrates (and translocation to the
membrane of the active isoform) and prevents any sub-
sequent substrate phosphorylation and activity [64]. For
nPKC, the PKC–RACK interaction occurs via a C2-like
domain that does not bind Ca2+ [64,65]. Thus, the clas-
sic calcium-dependent cPKCs are not inhibited with the
peptide εV1-2 because they do not possess this C2-like
region. In addition, studies using peptide translocation
inhibitors of nPKCε (εV1-2) and nPKCδ (δV1) demon-
strated that these isoforms (nPKCε and nPKCδ) can
have opposing actions within a given cell type (cardio-
myocyte) [66-68] and also showed the isoform specificity
of the peptides. There are several evidence that show
that the effects found using the nPKCε-specific transloca-
tion inhibitor peptide can be confirmed when nPKCε
knockout mice are used [69,70]. The effect of εV1-2
(100 μM) was studied in parallel to the effect of the scram-
bled version of this peptide (εV1-2-s, 100 μM). In some
experiments, stimulated muscles were previously incu-
bated with the peptide εV1-2 or with its inactive form
(30 minutes).
To activate PKC family with PMA, a potent but non-
selective-isoform PKC activator, the diaphragm muscles
were incubated for 10, 30 or 60 minutes on a Sylgard-
coated Petri dish containing Ringer solution for thecontrol muscles, or εV1-2 (100 μM), scrambled εV1-2
(100 μM) or PMA (10 nM).
Western blot analysis
Diaphragm muscles from newborn and adult rat were
dissected, frozen in liquid nitrogen, and stored at −80°C
before use. The muscles were homogenized using a
high-speed homogenizer (overhead stirrer, VWR Inter-
national, Clarksburg, MD) in lysis buffer containing
150 mM NaCl, 20 mM Tris–HCl, pH 7.5, 2 mM EGTA,
and 5 mM EDTA supplemented with 1% Triton X-100,
1 mM PMSF, 50 mM NaF, and 1 mM sodium orthova-
nadate from Sigma, (St. Louis, MO) and protease inhibi-
tor cocktail (Sigma-Aldrich Corp., Saint Louis, MO,
USA). Insoluble material was removed by centrifugation
at 1000 g for 10 minutes. The supernatants were col-
lected and centrifuged at 15000 g for 20 minutes. Finally,
the resulting supernatants (total protein lysates) were
collected. Protein concentrations were determined by
using the Bio-Rad DC protein assay (Bio-Rad, Hercules,
CA). Experimental procedures were performed to deter-
mine the linear and quantitative dynamic range for each
target protein and the appropriate dilutions of samples
were used for accurate and normalized quantitation by
means of densitometric analysis. Protein samples of 15
or 30 μg were separated by 8% SDS-polyacrylamide elec-
trophoresis and electrotransferred to PVDF membranes
(Hybond™-P; Amersham, GE Healthcare). The membranes
were blocked in Tris-buffered saline-0.1% Tween-20
(TBS-T) containing 5% (W/V) nonfat dry milk or in a
blocking reagent to preserve phosphoprotein antigens
(PhosphoBLOCKER™; Cell Biolabs, Inc.) and probed with
the primary antibody overnight at 4°C. The membranes
were then incubated with the secondary antibody and vi-
sualized enhanced chemiluminescence with the ECL kit
(Amersham Life Science, Arlington Heights, IL).
In treated and/or stimulated muscles, the synaptic
membranes were obtained. Synaptic and extrasynaptic
parts of the diaphragm muscle were separated as previ-
ously described [25]. We performed control experiments
to check that our protocol for dividing the diaphragm
muscle into synaptic and extrasynaptic region was accur-
ate. In some muscles, we repeated the process of separ-
ation and detected NMJs with TRITC-conjugated α-BTX.
We also stained the nerves with an antibody against anti-
neurofilament-200 and did not detect any nerves in extra-
synaptic regions. The muscles were homogenized using a
high-speed homogenizer (overhead stirrer, VWR Inter-
national, Clarksburg, MD) in lysis buffer (see above) and
the insoluble material was removed in the same way (by
centrifugation at 1000 g for 10 minutes) but now the
resulting supernatant was collected and centrifuged at
130000 g for 1 hour. The supernatant was the cytosolic
fraction, and the pellet was the membrane fraction. To
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cytosol, we used a goat antibody directed against Glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH), a protein
specific to the cytosolic fraction. GADPH immunoreactiv-
ity was not observed in any case in the membrane fraction.
The samples were processed the same way as another
sample of total protein (see below).
The blots were visualized with aVersaDoc 3000 (Bio-Rad,
Hercules, CA). The densitometry of different bands was
analyzed with the MetaMorph software. The integrated
optical density of the bands was normalized to the back-
ground values and by actin protein. Also, as another load-
ing control we used a total protein analysis (Sypro Ruby
protein blot Stain, Bio Rad) to measure the total protein
transferred on polyvininylidene difluoride (PVDF) mem-
branes. In all the cases, the quantitative results obtained
by using actin or total protein analysis were no different.
The relative variations between the bands in the experi-
mental samples and the control samples were calculated
in the same image. The data were taken from densitom-
etry measurements made in at least five separate experi-
ments, plotted against controls. Data are mean values ±
SD. Differences between groups were tested using the
t Student test or U test (Mann–Whitney), and the normal-
ity of the distributions was tested with the Kolmogorov–
Smirnov test. The criterion for statistical significance was
p < 0.05 versus the control.
Immunohistochemistry and confocal microscopy
Whole muscle mounts were processed by immunohisto-
chemistry to detect the localization of the nPKCε iso-
form at the NMJ. LAL and diaphragm muscles from
young adult rats were fixed with 4% paraformaldehyde
for 30 minutes. After fixation, the muscles were rinsed
with PBS and incubated in 0.1 M glycine in PBS. The
muscles were permeabilized with 0.5% Triton X-100 in
PBS, and nonspecific binding was blocked with 4% bo-
vine serum albumin (BSA). Then, muscles were incu-
bated overnight at 4°C in mixtures of three primary
antibodies raised in different species (anti-nPKCε iso-
form antibody and anti-syntaxin and anti-neurofilament
or syntaxin or anti-S100) and then rinsed. The muscles
were then incubated for four hours at room temperature
in a mixture of appropriate secondary antibodies. The
AChRs were detected with α-BTX conjugated with TRITC.
At least three muscles were used as negative controls as
described above. For a better analysis of the localization of
the nPKCε isoform at the NMJ, some muscles were proc-
essed to obtain semithin cross-sections from whole-mount
multiple-immunofluorescent stained muscles. This method
provided a simple and sensitive procedure for analyzing
the cellular distribution of molecules at the NMJ [24].
Labeled NMJs from the whole-mount muscles and the
semithin cross-sections were viewed with a laser-scanningconfocal microscope (Nikon TE2000-E). Special consider-
ation was given to the possible contamination of one
channel by another. In experiments involving negative
controls, the photomultiplier tube gains and black
levels were identical to those used for a labeled prep-
aration made in parallel with the control preparations.
At least 25 endplates per muscle were observed, and
at least six muscles were studied. Images were assem-
bled using Adobe PhotoShop software (Adobe
Systems, San Jose, CA) and neither the contrast nor
brightness were modified.
Electrophysiology
Diaphragm muscles from adult rats were removed surgi-
cally and incubated in a Sylgard-Petri dish containing
normal Ringer solution (in mM) – NaCl 135, KCl 5,
CaCl2 2.5, MgSO4 1, NaH2PO4 1, NaHCO3 15, glucose
11 – which was bubbled continuously with 95% O2, 5%
CO2. Temperature and humidity were regulated at 26°C
and 50%, respectively. Spontaneous miniature endplate
potentials (MEPPs) and evoked endplate potentials
(EPPs) were recorded intracellularly with conventional
glass microelectrodes filled with 3 M KCl (resistance:
20–40 MW). Recording electrodes were connected to an
amplifier (Tecktronics, AMS02), and a distant Ag-AgCl
electrode connected to the bath solution via an agar
bridge (agar 3.5% in 137 mM NaCl) was used as a refer-
ence. The signals were digitized (DIGIDATA 1322A
Interface, Axon Instruments Inc, CA, USA), stored and
computer-analyzed. The software Axoscope 9.0 (Axon
Instruments Inc, CA, USA) was used for data acquisition
and analysis. To prevent muscle contraction during EPP
recordings, we used μ-conotoxin GIIIB (μ-CgTx-GIIIB,
3 μM −1.5 μM, from ICS, International Clinical Service
GmbH, München). After a muscle fiber had been im-
paled, the phrenic nerve was continuously stimulated
(70 stimuli at 0.5 Hz) using two platinum electrodes that
were coupled to a pulse generator (CIBERTEC CS-20)
linked to a stimulus isolation unit. The last 50 EPPs were
recorded. We selected fibers with membrane potentials
of no less than -70 mV and used only those results from
preparations which did not deviate by more than 5 mV
during the recording. The mean amplitude (mV) per
fiber was calculated and corrected for non-linear summa-
tion (EPPs were usually more than 4 mV) [71] assuming a
membrane potential of – 80 mV. Quantal content (M)
was estimated by the direct method, which consists of re-
cording mEPPs and EPPs simultaneously and then calculat-
ing the ratio: M =Average Peak EPP/Average Peak mEPP.
We studied a minimum of 15 fibers per muscle and usually
a minimum of 5 muscles in each type of experiment. The
data given in Results are mean values ± SEM. Only one
hemidiaphragm was used from each animal for a given ex-
periment. We used the two-tailed Welch’s t-test (for
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equal). Differences were considered significant at P < 0.05
(*).
Denervation
Extensor digitorum longus (EDL) denervation. Young adult
rats (30–40 months of age, male) were anesthetized with
ketamine/xylazine (K/X; 0.1 ml/10 g body weight intraper-
itoneal injection of a solution containing 10 mg/ml keta-
mine and 1 mg/ml xylazine). To isolate the sciatic nerve, a
0.5 cm excision was made on the exterior side of the leg at
approximately 1 cm over the level of knee. The excision
was made carefully avoiding tissue injury, the sciatic nerve
was cut about 1 mm from the nerve’s entrance into the
muscle and a 1 cm segment was excised. The wound was
then closed. At the times desired (1–3 days), the rats were
anesthetized with pentobarbital and the EDL muscle was
excised.
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